Biospecimen Collection + Computed Tomography + Gallium Ga 68 Gozetotide + Positron Emission Tomography + Questionnaire Administration + Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Mar 2024: Trial registered, NCT06288113
  2. 1 Aug 2024: Trial started, NCT06288113

The trials

NCT06288113: Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

State
Under way
Phase
Phase 2
People
40 planned
Started
1 Aug 2024
Primary completion
27 Jan 2027
Arms
Treatment (177Lu-PSMA-617)
Results
None posted
  1. 1 Mar 2024: Trial registered
  2. 1 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.